Showing results (161-170 of 377) with videos related to
Sort By:
Pageof 38
European Journal of Cancer (Oxford, England : 1990)|September 18, 2022
HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implicationsPaolo Tarantino, Samuel M Niman, Timothy K Erick, et al.Cancer Research|March 20, 2024
A Subpopulation of Luminal Progenitors Secretes Pleiotrophin to Promote Angiogenesis and Metastasis in Inflammatory Breast CancerMengmeng Zhang, Kaiwen Zhou, Zilin Wang, et al.Journal of Telemedicine and Telecare|November 15, 2021
Telephone versus in-person genetic counseling for hereditary cancer risk: Patient predictors of differential outcomesSavannah Binion, Lia J Sorgen, Beth N Peshkin, et al.The New England Journal of Medicine|May 25, 2002
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutationsTimothy R Rebbeck, Henry T Lynch, Susan L Neuhausen, et al.Breast Cancer Research and Treatment|January 3, 2020
Predictors of contralateral prophylactic mastectomy in genetically high risk newly diagnosed breast cancer patientsMara Tynan, Beth N Peshkin, Claudine Isaacs, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2016
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3Fabrice André, Sara Hurvitz, Angelica Fasolo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2025
A phase Ib study of sapacitabine and olaparib in patients with BRCA1/2-mutated metastatic breast cancerFilipa Lynce, Noah Graham, Bose S Kochupurakkal, et al.Public Health Genomics|August 22, 2024
Streamlined Genetic Education and Cascade Testing in Men from Hereditary Breast Ovarian Cancer Families: A Randomized TrialChristopher Grisham, Beth N Peshkin, Lia Sorgen, et al.Breast Cancer Research : BCR|September 30, 2025
Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II studyKristina Fanucci, Eren D Yeh, Ruichao Shi, et al.Journal of Cancer Survivorship : Research and Practice|June 12, 2014
Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901Leigh Anne Faul, Gheorghe Luta, Vanessa Sheppard, et al.Pageof 38